Oxford Journal of Infectious Diseases (January 2023 issue Drop 1 of 3)

In this first issue of the OJID for 2023, we have some very interesting studies to go over.
It looks like the mRNA shots, being reverse transcribed into your DNA, is finally beginning to be taken seriously by mainstream academia. There's also some interesting studies on the rise in RSV cases during the last 3 years and something I covered in my series on the Pfizer FOIA documents releases.

1) Sensitivity of Reverse Trannoscription Polymerase Chain Reaction Tests for SARSCov 2 Through Time

2) Memory B-Cell Development After Asymptomatic or Mild Symptomatic SARS-CoV-2 Infection

3) Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19

4) Potent Neutralizing Activity of Polyclonal Equine Antibodies Against SARS Cov 2 Variants of Concern

5) SARS-CoV-2 Evolution and Patient Immunological History Shape the Breadth and Potency of Antibody- Mediated Immunity

Oxford Journal of Infectious Diseases (January 2023 issue Drop 2 of 3)

1) An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice

2) Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months

3) Perturbations in Respiratory Syncytial Virus Activity During the SARS-CoV-2 Pandemic

4) Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey

5) Differences in New Variant of Concern Replication at Physiological Temperatures In Vitro

6) Hyperimmune Globulin for Severely Immunocompromised Patients Hospitalized With Coronavirus Disease 2019: A Randomized, Controlled Trial

7) Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant

Oxford Journal of Infectious Diseases (January 2023 issue Drop 3 of 3)

1) Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers

2) A Pilot Trial of Thymalfasin (Thymosin-α-1) to Treat Hospitalized Patients With Hypoxemia and Lymphocytopenia Due to Coronavirus Disease 2019 Infection

3) Longitudinal Evaluation of Antibody Persistence in Mother-Infant Dyads After Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Pregnancy

4) Low Prevalence of Interferon α Autoantibodies in People Experiencing Symptoms of Post–Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID

5) Slow Waning of Antibodies Following BNT162b2 as a Third Dose in Adults Who Had Previously Received 2 Doses of Inactivated Vaccine